The efficacy and drug survival of the biosimilar infliximab (CT-P13) compared to the original reference infliximab in inflammatory rheumatic diseases; results from the Turkbio registry

Uslu, SadettinCan, GerçekŞenel, Sonerİnanç, NevsunAkar, ServetKocaer, Sinem BurcuBirlik, MerihÇapar, SedatAkkoç, NurullahÖnen, Fatoş2024-01-092024-01-092018-06Uslu, S. vd. (2018). ''The efficacy and drug survival of the biosimilar infliximab (CT-P13) compared to the original reference infliximab in inflammatory rheumatic diseases; results from the Turkbio registry''. Annals of the Rheumatic Diseases, 77(Supplement 2), 329-329.0003-49671468-2060https://doi.org/10.1136/annrheumdis-2018-eular.6440https://ard.bmj.com/content/77/Suppl_2/329https://hdl.handle.net/11452/38904Bu çalışma, 13-16 Haziran 2018 tarihlerinde Amsterdan[Hollanda]’da düzenlenen Congress of the European-League-Against-Rheumatism (EULAR) Kongresi‘nde bildiri olarak sunulmuştur.eninfo:eu-repo/semantics/openAccessRheumatologyThe efficacy and drug survival of the biosimilar infliximab (CT-P13) compared to the original reference infliximab in inflammatory rheumatic diseases; results from the Turkbio registryArticle00044435100102632932977Supplement 2Rheumatology